Document Detail

Renal hemodynamics in essential hypertensives treated with losartan.
MedLine Citation:
PMID:  7781206     Owner:  NLM     Status:  MEDLINE    
ACE-inhibitors are known to have special renal effects, i.e. they increase ERPF, decrease the filtration fraction and lower proteinuria. These effects can be due to a decrease in angiotensin II (AII) levels as well as an increase in bradykinin. New and more specific AII-receptor antagonists may help to distinguish between effects exerted by angiotensin II and those exerted by bradykinin. We investigated the effects of losartan in 9 patients with essential hypertension (sitting mean diastolic blood pressure 95-120 mmHg). Renal hemodynamics were measured by continuous inulin-and PAH-clearance (GFR and RPF) after stopping antihypertensive therapy for 1 week, followed by a 2-week placebo period and after a 4-week treatment phase with losartan (50 mg/die) followed by a therapy with an ACE-inhibitor (ramipril 5mg/die). Additionally, urine albumin excretion (UAE) was measured. Treatment of patients with essential hypertension with losartan resulted in a significant decrease of MAP after three weeks of treatment (121 +/- 8 mmHg under placebo and 114 +/- 10 mmHg under losartan; * = p < 0.05). MAP after four weeks of losartan treatment was 115 +/- 11 mmHg. Regarding changes in renal hemodynamics we could not demonstrate a significant change for neither losartan nor the ACE-inhibitor. Urine albumin excretion was reduced by both treatment regimens in correlation to the magnitude of blood pressure reduction. Our data indicate that losartan induced a significant reduction in MAP in patients with essential arterial hypertension with only moderate effects on renal hemodynamics.
C M Erley; B Bader; M Scheu; S Wolf; N Braun; T Risler
Related Documents :
3063286 - Antihypertensive effect of captopril, canrenoate potassium, and atenolol. relations wit...
2533076 - Regression of left ventricular hypertrophy on long-term treatment with captopril of sev...
8282366 - Effects of a metalloendopeptidase-24.15. inhibitor on renal hemodynamics and function i...
8886426 - Comparison of angiotensin ii type 1 receptor blockade and angiotensin-converting enzyme...
2477096 - Perspectives on clinical trials for hypertonic saline/dextran solutions for the treatme...
2633326 - The clinical significance of the reflux producing intrinsic bladder pressure and bladde...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical nephrology     Volume:  43 Suppl 1     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  1995 Jan 
Date Detail:
Created Date:  1995-07-14     Completed Date:  1995-07-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  S8-11     Citation Subset:  IM    
Section of Nephrology and Hypertension, University of Tübingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Biphenyl Compounds / therapeutic use*
Drug Therapy, Combination
Hydrochlorothiazide / therapeutic use
Imidazoles / therapeutic use*
Kidney / drug effects
Middle Aged
Ramipril / therapeutic use
Renal Circulation / drug effects*
Renin-Angiotensin System / drug effects
Tetrazoles / therapeutic use*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Imidazoles; 0/Tetrazoles; 114798-26-4/Losartan; 58-93-5/Hydrochlorothiazide; 87333-19-5/Ramipril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Does L-arginine alter proteinuria and renal hemodynamics in patients with chronic glomerulonephritis...
Next Document:  Multiorgan abnormalities in myotonic dystrophy--correlation among endocrine disorders, central nervo...